Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rimonabant.

Sheridan Henness1, Dean M Robinson, Katherine A Lyseng-Williamson

  • 1Wolters Kluwer Health-Adis, 41 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand. demail@adis.co.nz

Drugs
|November 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.

Drugs·2020
Same author

Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.

Drugs·2020
Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2020
Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019
Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019
Same author

Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Rimonabant, a cannabinoid receptor-1 blocker, effectively reduced weight and improved metabolic health in obese adults. It also demonstrated weight-independent benefits for glucose control and lipid profiles.

Area of Science:

  • Pharmacology
  • Metabolic Diseases
  • Obesity Research

Background:

  • The endocannabinoid system plays a role in regulating energy balance and metabolism.
  • Overactivity of this system is linked to obesity and associated metabolic disorders.
  • Selective cannabinoid receptor-1 (CB1) blockers offer a potential therapeutic strategy.

Purpose of the Study:

  • To evaluate the efficacy and safety of rimonabant in overweight or obese adults.
  • To assess rimonabant's impact on weight, waist circumference, and cardiometabolic risk factors.
  • To investigate potential weight-independent effects of rimonabant.

Main Methods:

  • Four randomized, double-blind clinical trials were conducted.
  • Participants included overweight or obese adults, with or without type 2 diabetes and/or dyslipidemia.

Related Experiment Videos

  • The treatment involved oral rimonabant 20mg once daily compared to placebo.

    • Main Results:

    • Rimonabant significantly reduced weight and waist circumference compared to placebo.
    • A greater proportion of rimonabant recipients achieved clinically significant weight loss targets (>5% or >10%).
    • Rimonabant improved glycemic control and lipid profiles (HDL-C, triglycerides) with significant weight-independent effects.

    Conclusions:

    • Rimonabant is an effective treatment for weight management in obese adults.
    • The drug offers cardiometabolic benefits beyond weight loss alone.
    • Rimonabant was generally well-tolerated, with mild to moderate adverse events.